Big Flats, NY, September 26, 2014 - X-GEN Pharmaceuticals, Inc. announced today that it is re-launching Nystatin Topical Powder USP, a generic product AT rated to Mycostatin®. Nystatin Topical Powder is an antibiotic used to treat skin infections caused by a wide variety of yeasts. X-GEN received FDA approval for Nystatin Topical in December of [...]
Big Flats, NY, May 19, 2014 — X-GEN Pharmaceuticals announced today it will begin marketing and distributing Polymyxin B for Injection, USP in a 10 pack carton. The new arrival is a product line extension to X-GEN’s current Polymyxin B drug, which is used to prevent infections that are strongly suspected or proven to be [...]
Big Flats, NY – (February 17, 2014) - X-GEN Pharmaceuticals announced today FDA approval to begin marketing and distributing Clonidine Hydrochloride Injection as part of a development and licensing agreement with Exela Pharma Sciences. Exela Pharma Sciences developed and is the commercial manufacturer of the drug product. Clonidine is AP rated to Duraclon® and is [...]
Big Flats, NY – (August, 2013) - X-GEN Pharmaceuticals, Inc. announces FDA approval to begin marketing and distributing Tranexamic Acid Injection. Tranexamic Acid is the generic product AP rated to Cyklokapron® and works by blocking the breakdown of blood clots in hemophiliacs. Tranexamic Acid reduces or prevents hemorrhage and can also minimize the potential need [...]
Big Flats, NY – (June 14, 2013) - X-GEN Pharmaceuticals, Inc. today announced that it is a winner of the first Legacy Award, presented by the Premier healthcare alliance. Premier, a provider-owned performance improvement alliance of 2,800 hospitals and nearly 100,000 other care sites, contracts with more than 1,000 suppliers. X-GEN is one of 18 [...]
